Pyrotinib

CAT: 0804-HY-104065-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-104065-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively[1].
CAS Number
[1269662-73-8]
Product Name Alternative
SHR-1258
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Pyrotinib.html
Purity
99.89
Solubility
0.1 M Maleic Acid : 16.67 mg/mL (ultrasonic) |1 M Maleic Acid : 100 mg/mL (ultrasonic) |DMSO : 10 mg/mL (ultrasonic; adjust pH to 6 with HCl)
Smiles
O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)C2=C1)/C=C/[C@@H]5N(C)CCC5
Molecular Formula
C32H31ClN6O3
Molecular Weight
583.08
Precautions
H302, H315, H319, H335
References & Citations
[1]Li X, et al. Discovery and development of Pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017 Jan 21. pii: S0928-0987 (17) 30043-X.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
EGFR/ErbB1/HER1; ErbB2/HER2
Citation 01
Biomed Pharmacother. 2024 Nov:180:117523.|Biosci Rep. 2020 Feb 28;40 (2) :BSR20194167.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Clin Transl Oncol. 2024 May 25.|Int J Biol Macromol. 2023 Jul 1;242 (Pt 2) :124870.|iScience. 2024 Jan 9;27 (2) :108839.|J Exp Clin Cancer Res. 2025 Aug 19;44 (1) :245.|J Med Chem. 2019 May 9;62 (9) :4772-4778.|J Thorac Oncol. 2024 Jan;19 (1) :106-118.|Lung Cancer. 2018 Dec:126:72-79.|Mol Syst Biol. 2024 Jan;20 (1) :28-55.|Nat Cancer. 2025 Jul;6 (7) :1202-1222.|Patent. US 20220175778A1.|Patent. US20210361655A1.|Patent. US20250312348A1.|STAR Protoc. 2024 Apr 16;5 (2) :102987.|Int J Cancer. 2024 Jul 15;155 (2) :324-338.|Open Life Sci. 2023 Jan 10;18 (1) :20220535.

Related Products

CatalogName
HY-124613Pyrazinib

Alternative Products

CatalogName
OR1103291-01Pyrotinib
BUP12739-01Pyrotinib dimaleate
A19423-1Pyrotinib 1mg
MBS3601662-01Pyrotinib maleate
MBS5785418-01(Rac)-Pyrotinib
TRC-P997509-10MGPyrotinib-d3
A19423-25Pyrotinib 25mg
A19423-10Pyrotinib 10mg
MBS3842043-01Pyrotinib Racemate
A19423-5Pyrotinib 5mg

Popular Products